AU2022255073A1 - 2,4-diaminopyrimidine derivatives as ulk1/2 inhibitors and their use thereof - Google Patents

2,4-diaminopyrimidine derivatives as ulk1/2 inhibitors and their use thereof Download PDF

Info

Publication number
AU2022255073A1
AU2022255073A1 AU2022255073A AU2022255073A AU2022255073A1 AU 2022255073 A1 AU2022255073 A1 AU 2022255073A1 AU 2022255073 A AU2022255073 A AU 2022255073A AU 2022255073 A AU2022255073 A AU 2022255073A AU 2022255073 A1 AU2022255073 A1 AU 2022255073A1
Authority
AU
Australia
Prior art keywords
alkyl
compound
pharmaceutically acceptable
stereoisomer
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2022255073A
Other languages
English (en)
Inventor
Martin AMBLER
Edward Giles Mciver
Chidochangu MPAMHANGA
Simon Osborne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LifeArc
Original Assignee
LifeArc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LifeArc filed Critical LifeArc
Publication of AU2022255073A1 publication Critical patent/AU2022255073A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2022255073A 2021-04-07 2022-04-06 2,4-diaminopyrimidine derivatives as ulk1/2 inhibitors and their use thereof Abandoned AU2022255073A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163171763P 2021-04-07 2021-04-07
US63/171,763 2021-04-07
PCT/IB2022/000182 WO2022214869A2 (en) 2021-04-07 2022-04-06 Ulk1/2 inhibitors and their use thereof

Publications (1)

Publication Number Publication Date
AU2022255073A1 true AU2022255073A1 (en) 2023-11-23

Family

ID=81748947

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022255073A Abandoned AU2022255073A1 (en) 2021-04-07 2022-04-06 2,4-diaminopyrimidine derivatives as ulk1/2 inhibitors and their use thereof

Country Status (8)

Country Link
US (1) US20240208934A1 (https=)
EP (1) EP4320121A2 (https=)
JP (1) JP2024516359A (https=)
KR (1) KR20240025504A (https=)
CN (1) CN117545751A (https=)
AU (1) AU2022255073A1 (https=)
CA (1) CA3214567A1 (https=)
WO (1) WO2022214869A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024140401A1 (zh) * 2022-12-30 2024-07-04 捷思英达控股有限公司 作为激酶抑制剂的杂环化合物以及包括其的组合物
WO2025045203A1 (zh) * 2023-09-01 2025-03-06 葆元生物医药科技(杭州)有限公司 杂环化合物及其中间体和应用
WO2025045182A1 (zh) * 2023-09-01 2025-03-06 深圳众格生物科技有限公司 Ulk1抑制剂及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
ATE407678T1 (de) * 2001-10-17 2008-09-15 Boehringer Ingelheim Pharma Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
PE20220597A1 (es) * 2019-05-10 2022-04-22 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos

Also Published As

Publication number Publication date
CN117545751A (zh) 2024-02-09
KR20240025504A (ko) 2024-02-27
WO2022214869A2 (en) 2022-10-13
CA3214567A1 (en) 2022-10-13
US20240208934A1 (en) 2024-06-27
EP4320121A2 (en) 2024-02-14
WO2022214869A3 (en) 2022-11-24
JP2024516359A (ja) 2024-04-15

Similar Documents

Publication Publication Date Title
CN115151304B (zh) 小分子干扰素基因刺激因子(sting)拮抗剂
US9428508B2 (en) 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as FAK/Pyk2 inhibitors
AU2022255073A1 (en) 2,4-diaminopyrimidine derivatives as ulk1/2 inhibitors and their use thereof
TWI870770B (zh) Parp1抑制劑及其用途
JP7337395B2 (ja) Ｃｄｋ４およびｃｄｋ６阻害剤としての２ｈ－インダゾール誘導体およびその治療上の使用
CA3124898A1 (en) Heterocyclic compound, intermediate, preparation method therefor and application thereof
CN119546588A (zh) 吡啶检查点激酶1（chk1）抑制剂及其用途
KR20210095634A (ko) Tyk2 억제제 및 이의 용도
CA2915561A1 (en) Novel substituted bicyclic compounds as bromodomain inhibitors
CN116783165A (zh) 作为用于治疗癌症的yap/taz-tead激活抑制剂的1,2,3,4-四氢喹啉衍生物
CA3050853A1 (en) Heterocyclic spiro compounds as magl inhibitors
US12410179B2 (en) Modulators of TNF alpha activity and uses thereof
US20250188094A1 (en) Pyrazole membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof
CA3196676A1 (en) Pyrimidine compounds, compositions, and medicinal applications thereof
US20260008770A1 (en) Cbl-b inhibitors and methods of uses thereof
CA2946475A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
TW202340190A (zh) 外核苷酸焦磷酸酶-磷酸二酯酶(enpp1)抑制劑及其用途
KR20250023339A (ko) 페닐 트라이아졸 mll1-wdr5 단백질-단백질 상호작용 저해제
WO2023241627A1 (en) Cdk8/19 dual inhibitors and methods of use thereof
JP2025522274A (ja) Ｐａｒｇの阻害剤
CN120752230A (zh) Kif18a的抑制剂及其用途
JP2024534421A (ja) スルファミドリボヌクレオチドレダクターゼ（ｒｎｒ）阻害剤およびその使用
EP4626433A1 (en) Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof
HK40106135A (zh) 作为ulk1/2抑制剂的2，4-二氨基嘧啶衍生物及其用途
WO2026096285A1 (en) Pyridine derivatives for treating cancer

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period